Form 4 for NVCR NovoCure Ltd
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001562180-24-001980 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-29 | 2024-02-28 | NVCR | GROENHUYSEN WILHELMUS CM | COO | S - Sale | $16.14 | -2,303 | 254.6K | -0.9% | -$37.2K |
| DM | 2024-02-29 | 2023-12-31+ | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $16.30 | +47.0K | 209.8K | +29% | +$766.7K |
| D | 2024-02-29 | 2024-02-27 | NVCR | GROENHUYSEN WILHELMUS CM | COO | A - Grant | $16.30 | +71.9K | 71.9K | New | +$1.17M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-02-28 | S | D | 2,303 | $16.14 | 254,559 | D | — | — | (F4) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| 2 | Common | Ordinary Shares | 2024-02-27 | A | A | 47,034 | $16.30 | 256,862 | D | — | — | (F3) Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. |
| 3 | Common | Ordinary Shares | 2023-12-31 | A | A | 3 | $12.69 | 209,828 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c). (F2) In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023. |
| 4 | Derivative | Stock Options (Right to buy) | 2024-02-27 | A | A | 71,920 | $16.30 | 71,920 | D | $16.30 · 2025-02-27 to 2034-02-26 | 71,920 Ordinary Shares | (F5) Options to buy 71,920 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. |